A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

NCT07633756 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Phase 1b
Open Label
REC-617
RB1-Negative
Leiomyosarcoma

Interventions

DRUG: REC617

Sponsor

M.D. Anderson Cancer Center